Corrigendum to: Histone deacetylases enzyme, copper, and IL-8 levels in patients with Alzheimer’s disease. (Am J Alzheimers Dis Other Demen., (2013), 28, 1, (54-61), 10.1177/1533317512467680);Histone deacetylases enzyme, copper, and IL-8 levels in patients with Alzheimer's disease

American Journal of Alzheimer's Disease and other Dementias

Volumn 28, Issue 1, 2013, Pages 54-61

  Alsadany, Mohamad A ^a   Shehata, Hanan H ^a   Mohamad, Magda I ^a   Mahfouz, Riham G ^b  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b MENOUFIA UNIVERSITY   (Egypt)

Author keywords

AD; Cognitive function; Copper; Epigenetics; HDACs; IL 8; Inflammation

Indexed keywords

BIOLOGICAL MARKER; COPPER; HISTONE DEACETYLASE; INTERLEUKIN 8;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; COPPER BLOOD LEVEL; DISEASE COURSE; DISEASE DURATION; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; PROTEIN BLOOD LEVEL; PSYCHOLOGIC TEST; RECALL; SENSITIVITY AND SPECIFICITY; WORD LIST RECALL;

EID: 84876475030     PISSN: 15333175     EISSN: 19382731     Source Type: Journal    
DOI: 10.1177/1533317518786149     Document Type: Erratum

References (49)

1. Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci. 2009;11(2):111-128.
2. Vicioso BA. Dementia: when is it not Alzheimer's disease? Am J Med Sci. 2002;324(2):84-95. (Pubitemid 34851731)
3. Zawia NH, Lahiri DK, Cardozo-Pelaez F. Epigenetics, oxidative stress and Alzheimer's disease. Free Radic Biol Med. 2009;46(9): 1241-1249.
4. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004;430(7000):631-639. (Pubitemid 39061671)
5. Abel Ted, Suzanne Zukin R. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr Opin Pharmacol. 2008;8(1):57-64.
6. Scarpa S, Cavallaro RA, D'Anselmi F, Fuso A. Gene silencing through methylation: an epigenetic intervention on Alzheimer disease. J Alzheimers Dis. 2006;9(4):407-414. (Pubitemid 44253355)
7. Kouzarides T. Chromatin modifications and their function. Cell. 2007;128(4):693-705. (Pubitemid 46273577)
8. Lee KK, Workman JL. Histone acetyltransferase complexes: one size doesn't fit all. Nat Rev Mol Cell Biol. 2007;8(4): 284-295. (Pubitemid 46474661)
9. Carey N, La Thangue NB. Histone deacetylase inhibitors: gathering pace. Curr Opin Pharmacol. 2006;6(4):369-375. (Pubitemid 44040838)
10. Lee J, Ryu H. Epigenetic modification is linked to Alzheimer's disease: is it a maker or a marker? BMB Rep. 2010;43(10): 649-655.
11. Mueller C, Schrag M, Crofton A, et al. Altered serum iron and copper homeostasis predicts cognitive decline in mild cognitive impairment. J Alzheimers Dis. 2012;29(2):341-350.
12. Kaden D, Bush AI, Danzeisen R, Bayer TA, Multhaup G. Disturbed copper bioavailability in Alzheimer's disease. Int J Alzheimers Dis. 2011;2011:345614.
13. Tuppo EE, Hugo R, Arias HR. The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol. 2005;37(2):289-305. (Pubitemid 39330191)
14. Li K, Liu S, Yao S, Wang B, Dai D, Yao L. Interaction between interleukin-8 and methylenetetrahydrofolate reductase genes modulates Alzheimer's disease risk. Dement Geriatr Cogn Disord. 2009;27(3):286-291.
15. DSM-IV-TR. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Revision. Washington DC: 2000; American Psychiatric Association.
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34(7):939-944. (Pubitemid 14076461)
17. Greicius MD, Geschwind MD, Miller BL. Presenile dementia syndromes: an update on taxonomy and diagnosis. J Neurol Neurosurg Psychiatry. 2002;72(6):691-700. (Pubitemid 34557008)
18. El-Okl MA, EL banouby MH, Mortagy AK, et al. Prevalence of AD and other types of dementia in Egypt. Tenth Congress of the International Psychogeriatrics Association. Int Psychogeriatr. 2001;13(2):114.
19. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
20. Morris JC, Heyman A, Mohs RC, et al. The consortium to establish a registry for Alzheimer's disease. part I: clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 1989;39(9):1159-1165. (Pubitemid 19239715)
21. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest Suppl. 1968;97:77-89.
22. Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000;403(6765):41-45. (Pubitemid 30038513)
23. Hack CE, Hart M, van Schijndel RJ, et al. Interleukin-8 in sepsis: relation to shock and inflammatory mediators. Infect Immun. 1992;60(7):2835- 2842.
24. Makino T, Takahara K. Direct determination of plasma copper and zinc in infants by atomic absorption with discrete nebulization. Clin Chem. 1981;27(8):1445-1447. (Pubitemid 11041590)
25. Morris JC. Clinical assessment of Alzheimer's disease. Neurology. 1997;49(3 suppl 3):S7-S10. (Pubitemid 27391791)
26. Rosen WG. Verbal fluency in aging and dementia. J Clin Neuropsychol. 1980;2(2):135-146. (Pubitemid 11220403)
27. Atkinson RC, Shiffrin RM. The control of short term memory. Sci Am. 1971;225(2):82-90.
28. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141(11):1356-1364.
29. Mohs RC, Kim Y, Johns CA. Assessing change in Alzheimer's disease: memory and language tests. In: Poon LW, ed. Handbook for clinical memory assessment of older adults, 1986. Washington, DC: American Psychological Association:149-155.
30. Welsh KA, Butters N, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's disease (CERAD) Part V normative study of the neuropsychological battery. Neurology. 1992;44(4):609-614. (Pubitemid 24129983)
31. Guan JS, Haggarty SJ, Giacometti E, et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature. 2009;459(7243):55-60.
32. Ryu H, Lee J, Hagerty SW, et al. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc Natl Acad Sci U S A. 2006;103(50):19176-19181. (Pubitemid 350002846)
33. Ferrante RJ, Kubilus JK, Lee J, et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci. 2003;23(28):9418-9427. (Pubitemid 37323042)
34. Squitti R, Lupoi D, Pasqualetti P, et al. Elevation of serum copper levels in Alzheimer disease. Neurology. 2002;59(8): 1153-1161. (Pubitemid 35192384)
35. Squitti R, Pasqualetti P, Dal Forno G, et al. Excess of serum copper not related to ceruloplasmin in Alzheimer disease. Neurology. 2005;64(6):1040-1046. (Pubitemid 40388458)
36. Magaki S, Raghavan R, Mueller C, Oberg KC, Vinters HV, Kirsch WM. Iron, copper, and iron regulatory protein 2 in Alzheimer's disease and related dementias. Neurosci Lett. 2007;418(1): 72-76. (Pubitemid 46602696)
37. Schrag M, Mueller C, Oyoyo U, Smith MA, Kirsch WM. Iron, zinc and copper in the Alzheimer's disease brain: a quantitative meta-Analysis. Some insight on the influence of citation bias on scientific opinion. Prog Neurobiol. 2011;94(3):296-306.
38. Kang J, Lin C, Chen J, Liu Q. Copper induces histone hypoacetylation through directly inhibiting histone acetyltransferase activity. Chem Biol Interact. 2004;148(3):115-123. (Pubitemid 38987829)
39. Lee KS, Chung JH, Choi TK, Suh SY, Oh BH, Hong CH. Peripheral cytokines and chemokines in Alzheimer's disease. Dement Geriatr Cogn Disord. 2009;28(4):281-287.
40. Sokolova A, Hill MD, Rahimi F, Warden LA, Halliday GM, Shepherd CE. Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease. Brain Pathol. 2009;19(3):392-398.
41. Zhang J, Sokal I, Peskind ER, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008;129(4):526-529. (Pubitemid 352029270)
42. Swardfager W, Lanctô t K, Rothenburg L, Wong A, Cappell J, Herrmann N. A meta-Analysis of cytokines in Alzheimer's disease. Biol Psychiatry. 2010;68(10):930-941.
43. Zuliani G, Guerra G, Ranzini M, et al. High interleukin-6 plasma levels are associated with functional impairment in older patients with vascular dementia. Int J Geriatr Psychiatry. 2007;22(4): 305-311. (Pubitemid 46680841)
44. Kim SM, Song J, Kim S, et al. Identification of peripheral inflammatory markers between normal control and Alzheimer's disease. BMC Neurol. 2011;11:51.
45. De Luigi A, Pizzimenti S, Quadri P, et al. Peripheral inflammatory response in Alzheimer's disease and multiinfarct dementia. Neurobiol Dis. 2002;11(2):308-314. (Pubitemid 36135694)
46. Grammas P, Samany PG, Thirumangalakudi L. Thrombin and inflammatory proteins are elevated in Alzheimer's disease microvessels: implications for disease pathogenesis. J Alzheimers Dis. 2006;9(1):51-58.
47. Galimberti D, Schoonenboom N, Scheltens P, et al. Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer's disease. Arch Neurol. 2006;63(4):538-543.
48. Angelopoulos P, Agouridaki H, Vaiopoulos H, et al. Cytokines in Alzheimer's disease and vascular dementia. Int J Neurosci. 2008; 118(12):1659-1672.
49. McAfoose J, and Baune BT. Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev. 2009;33(3):355-366.